Literature DB >> 10846711

[External quality assurance of inpatient treatment in schizophrenia. results of a multicenter study].

B Janssen1, C Burgmann, U Habel, T Held, P Hoff, M Jänner, H Mecklenburg, C Prüter, A Ruth, H Sass, F Schneider, W Gaebel.   

Abstract

Due to legal regulations, external quality assurance is mandatory in Germany. Supported by the German Health Ministry (BMG), we present the results of a multicenter study in four hospitals with different structures on 1042 inpatients with the tracer diagnosis of schizophrenia (ICD 10). We defined disease-specific indicators of structure, process, and outcome quality, developed an assessment instrument, and implemented a feedback system for quality comparison. The resulting quality profiles are useful as a starting point for internal quality management.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10846711     DOI: 10.1007/s001150050570

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  3 in total

1.  [Data supporting quality circle management of inpatient depression treatment].

Authors:  S Brand; M Härter; P Sitta; D van Calker; R Menke; A Heindl; K Herold; R Kudling; C Luckhaus; U Rupprecht; Dirk Sanner; D Schmitz; E Schramm; M Berger; W Gaebel; F Schneider
Journal:  Nervenarzt       Date:  2005-07       Impact factor: 1.214

2.  [Guideline conformity and outcome of inpatient treatment for schizophrenia. A clinical comparison].

Authors:  B Janssen; S Weinmann; M Berger; M Härter; T Held; M Leipert; H J Luderer; M Schwarz; T Steinert; W Gaebel
Journal:  Nervenarzt       Date:  2005-03       Impact factor: 1.214

3.  [Evaluation of therapy outcome on a psychiatric admission ward. Background, methods and first results of a project on quality management].

Authors:  Anja Wilkening; Michael Zeschky; Marc Ziegenbein; Hans Pfefferer-Wolf; Elke Harms; Gudrun Lübbe; Renate Bläsing; Matthias Albert; Wielant Machleidt; Iris Tatjana Calliess
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.